Lamotrigine (LTG) is a broad-spectrum antiepileptic drug with efficacy against both partial and generalized seizures. Many consider LTG to be an important alternative treatment for refractory generalized epilepsies in epilepsy patients with developmental disabilities (DD).
In a double-blind, placebo-controlled trial of LTG in treating the Lennox-Gastaut syndrome,88 33% of patients receiving LTG experienced a reduction in seizure frequency of at least 50%. This study noted minimal behavioral effects.
Two subsequent series found significant effects, both positive and negative, among DD epilepsy patients treated with LTG:
LTG now is being used for treatment-resistant bipolar disorder.91–93 Although more published double-blind trials address the use of carbamazepine and valproic acid, LTG (as well as gabapentin) appears to have a more favorable side effect profile, making it a better choice for mood stabilization in bipolar disorder.
A positive psychotropic effect of LTG is supported by the observation that several epilepsy patients who were entered in a randomized double-blind study of LTG and experienced only slight reductions in seizure severity still elected to remain in the drug trial and demonstrated elevated mood on quality-of-life measures.94 Meador and Baker95 also have shown LTG to possess favorable behavioral and cognitive effects.
DD patients receiving LTG should be observed for the development of allergic reactions, including pruritus and rash, which can progress to potentially life-threatening Stevens- Johnson syndrome.96
Reviewed and revised June 2004 by Steven C. Schachter, MD, epilepsy.com Editorial Board.
© 2013 Epilepsy.com. All rights reserved.